NM
AXDX

Newtyn Management’s Accelerate Diagnostics AXDX Stock Holding History

Newtyn Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-60,000
Closed -$12.4M – 21
2016
Q4 		$12.4M Hold
60,000
– – 2.06% 11
2016
Q3 		$16.4M Buy
+60,000
New +$13.3M 3.83% 10

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return

Newtyn Management's AXDX Position: Q1 2017 in Review

Newtyn Management sold out of Accelerate Diagnostics (AXDX) in Q1 2017, closing a stake of 60,000 shares — an estimated $12.4M sold.

Newtyn Management first reported a position in AXDX in Q3 2016 and held it in 2 quarters. The position peaked at $16.4M in Q3 2016. 98 funds tracked by Wall St. Rank hold AXDX as of Q1 2017.

  • Newtyn Management reported no remaining Accelerate Diagnostics position as of Q1 2017 after selling out during the quarter.
  • Newtyn Management sold 60,000 Accelerate Diagnostics shares in Q1 2017, an estimated $12.4M.
  • Newtyn Management first reported a position in Accelerate Diagnostics in Q3 2016 and held it in 2 quarters.
  • Newtyn Management's Accelerate Diagnostics position peaked at $16.4M in Q3 2016.
  • 98 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2017.

Based on Newtyn Management's 13F filing for Q1 2017, filed 15 May 2017.